Exogenous Allergic Alveolitis (Hypersensitivity Pneumonitis) – A Comprehensive Patient Guide

Overview

Exogenous allergic alveolitis (EAA), more commonly known as hypersensitivity pneumonitis (HP), is an immune‑mediated inflammation of the lung parenchyma and small airways that occurs after repeated inhalation of a wide variety of environmental antigens (often organic particles such as mold spores, animal proteins, or chemicals). The reaction is not an infection; it is a type III/IV hypersensitivity response that can become chronic if exposure continues.

HP can affect anyone who is repeatedly exposed to offending antigens, but certain occupations and hobbies place individuals at higher risk.

• Typical age: 20–60 years, though children and the elderly can be affected.
• Gender: Slight female predominance in some series (likely due to occupational exposure patterns).
• Prevalence: Exact rates are hard to determine because the disease is under‑diagnosed. In the United States, epidemiologic studies estimate an incidence of 1–2 cases per 100,000 adults per year, with higher rates (up to 10 per 100,000) among agricultural workers and bird‑exposure groups.^{[1] CDC, 2022}

Symptoms

Symptoms vary depending on whether the disease is acute, sub‑acute, or chronic. They can appear within hours of exposure or develop insidiously over months to years.

Acute HP (hours to days after exposure)

• Fever & chills – often low‑grade (37.5–38.5 °C).
• Dry, non‑productive cough – may be sudden in onset.
• Shortness of breath – especially on exertion.
• Chest tightness or “flu‑like” feeling.
• Fatigue & malaise.
• Myalgias (muscle aches) in some cases.

Sub‑acute HP (weeks to months of repeated exposure)

• Persistent cough (often dry).
• Gradual dyspnea on minimal activity.
• Low‑grade fever or intermittent chills.
• Weight loss & loss of appetite.
• Generalized fatigue.

Chronic HP (months to years)

• Progressive shortness of breath, especially with exertion.
• Dry cough that may become productive with sputum.
• Clubbing of fingertips (in advanced fibrosis).
• Chest discomfort or “tightness”.
• Exercise intolerance.
• Weight loss, malaise, and sometimes cyanosis in severe cases.

Causes and Risk Factors

HP occurs after inhalation of a sensitizing antigen that triggers an abnormal immune response. The antigens are grouped into several categories:

• Bird proteins: Feather, droppings, or serum from parrots, pigeons, canaries, and other pet birds (often termed “bird‑fancier’s lung”).
• Molds & fungi: Penicillium, Aspergillus, Thermophilic actinomycetes found in hay, straw, compost, or water‑damaged buildings.
• Thermophilic actinomycetes: Bacteria in moldy hay → “farmer’s lung”.
• Animal proteins: Exposure to livestock, particularly in dairy farms or meat‑processing plants.
• Low‑molecular‑weight chemicals: Isocyanates, metal dusts, epoxy resins, and certain cleaning agents.
• Others: Mycobacteria (e.g., “hot‑tub lung”), certain plant spores, and even some pharmaceuticals that act as inhaled haptens.

Risk Factors

• Occupational exposure: Farmers, bird breeders, mushroom growers, woodworkers, metal workers, textile workers, and health‑care workers handling disinfectants.
• Hobbies: Bird‑keeping, indoor gardening, antique restoration, and “hot‑tub” use with poorly maintained water.
• Genetic predisposition: Certain HLA‑DR alleles (e.g., HLA‑DRB1*13) have been linked to increased susceptibility.^{[2] NEJM, 2021}
• Smoking: Paradoxically, smokers may have a blunted acute response but are at higher risk for chronic fibrosis.
• Immune status: Immunocompromised patients may have atypical presentations.

Diagnosis

Diagnosing HP requires a combination of clinical history, imaging, functional testing, and sometimes tissue sampling. No single test is definitive.

Step‑by‑step approach

1. Detailed exposure history: Identify possible antigens (workplace, home, hobbies).
2. Physical examination: May reveal inspiratory crackles (especially at lung bases) or clubbing in chronic disease.
3. Pulmonary function tests (PFTs): Typically show a restrictive pattern (↓ FVC) and reduced diffusion capacity (DLCO). In early disease, a mixed obstructive‑restrictive pattern can be seen.
4. Chest imaging:
   • High‑resolution CT (HRCT): The gold‑standard radiologic tool. Acute HP shows diffuse ground‑glass opacities and centrilobular nodules; chronic HP shows reticulation, honeycombing, and fibrosis, often with upper‑lobe predominance.
   • Chest X‑ray: May be normal early; later shows diffuse haziness.
5. Laboratory tests:
   • Serum precipitating antibodies (IgG) against specific antigens (e.g., avian or mold extracts). Positive results support the diagnosis but are not exclusive.
   • Complete blood count (CBC) may reveal mild leukocytosis.
6. Bronchoalveolar lavage (BAL): Typically yields a lymphocyte‑predominant (>20‑30 %) fluid, helping differentiate HP from other interstitial lung diseases.
7. Lung biopsy (surgical or transbronchial): Reserved for ambiguous cases. Histology shows interstitial infiltrates of lymphocytes, poorly formed granulomas, and loosely organized fibroblastic foci.
8. Provocation testing (rarely used): Controlled re‑exposure to the suspected antigen under medical supervision; positive reaction confirms causality.

Diagnosis is most reliable when at least three of the following are present: compatible exposure, characteristic HRCT findings, BAL lymphocytosis, and improvement after antigen avoidance.^{[3] ATS/JRS/ALAT Guidelines, 2020}

Treatment Options

Therapy centers on removing the offending antigen and controlling inflammation. The approach varies by disease stage.

1. Antigen avoidance

• Identify and eliminate exposure (e.g., change work duties, improve ventilation, use respirators, stop bird‑keeping).
• Environmental remediation—professional cleaning of mold‑contaminated spaces, water‑damage repair.

2. Pharmacologic therapy

• Corticosteroids: First‑line for acute and sub‑acute HP.
  • Prednisone 0.5–1 mg/kg/day for 2–4 weeks, then taper based on clinical response.
  • Rapid symptom relief (often within days) but does not reverse established fibrosis.
• Steroid‑sparing agents (for chronic or steroid‑refractory cases):
  • Azathioprine 2 mg/kg/day.
  • Mycophenolate mofetil 1–1.5 g twice daily.
  • Rituximab has shown benefit in small case series of refractory HP.^{[4] Chest, 2022}
• Antifibrotic agents: Nintedanib (approved for progressive fibrosing ILDs, including HP) can slow decline in lung function in chronic disease.^{[5] FDA, 2020}

3. Supportive care

• Oxygen supplementation for resting hypoxemia (SpO₂ < 88%).
• Pulmonary rehabilitation – improves exercise capacity and quality of life.
• Vaccinations: Influenza, COVID‑19, and pneumococcal vaccines to prevent respiratory infections.

4. Surgical options

• In end‑stage disease with severe fibrosis, lung transplantation is an option for select patients.

Living with Exogenous Allergic Alveolitis (Hypersensitivity Pneumonitis)

Managing HP is a lifelong endeavor focused on preventing re‑exposure and preserving lung function.

• Environmental control: Use HEPA filters at home, keep humidity < 60 % to inhibit mold growth, and store hay or organic material outdoors.
• Personal protective equipment (PPE): When exposure cannot be avoided (e.g., certain jobs), wear N‑95 or higher respirators, goggles, and protective clothing.
• Regular monitoring: Schedule pulmonary function tests every 3–6 months; track symptoms in a diary.
• Medication adherence: Take steroids exactly as prescribed; never stop abruptly without tapering.
• Stay active: Low‑impact aerobic exercise (walking, stationary bike) improves ventilation and reduces dyspnea.
• Nutrition: A balanced diet rich in antioxidants (fruits, vegetables) supports immune health; maintain a healthy weight to reduce respiratory workload.
• Support networks: Join patient groups (e.g., American Lung Association) for education and emotional support.

Prevention

Because HP is triggered by inhaled antigens, reducing exposure is the cornerstone of prevention.

1. Identify high‑risk environments: Farms, bird‑keeping facilities, hot tubs, compost piles, and workplaces with dust or chemicals.
2. Improve ventilation: Install local exhaust fans, use air‑exchange systems, and keep windows open when safe.
3. Regular cleaning: Wet‑mop floors, use HEPA‑filtered vacuums, and promptly address water leaks.
4. Protective gear: Fit‑tested respirators, especially during tasks that generate dust or aerosols.
5. Environmental testing: Professional assessment for mold spores or endotoxins if chronic symptoms arise.
6. Medical surveillance: Workers with known exposure should have baseline PFTs and periodic follow‑up.

Complications

If exposure continues or disease progresses, several serious complications can develop:

• Pulmonary fibrosis: Irreversible scarring leading to chronic restrictive lung disease.
• Respiratory failure: Advanced fibrosis may require long‑term oxygen or mechanical ventilation.
• Secondary infections: Steroid therapy increases risk for bacterial, viral, and fungal pneumonia.
• Cor pulmonale: Right‑heart strain due to chronic hypoxia.
• Bronchogenic carcinoma: Some studies suggest an elevated risk in chronic interstitial lung disease, though data are limited.^{[6] Thorax, 2019}

When to Seek Emergency Care

---

References:
[1] Centers for Disease Control and Prevention. “Hypersensitivity Pneumonitis – Occupational Overview.” 2022.
[2] Guo, L. et al. “HLA‑DRB1*13 Association with Bird‑Fancier’s Lung.” New England Journal of Medicine, 2021.
[3] American Thoracic Society/Japanese Respiratory Society/Latin American Thoracic Association. “Guidelines for Diagnosis of Hypersensitivity Pneumonitis.” Am J Respir Crit Care Med, 2020.
[4] D’Alessandro, M. et al. “Rituximab in Refractory Chronic Hypersensitivity Pneumonitis.” Chest, 2022.
[5] U.S. Food & Drug Administration. “Nintedanib (Ofev) for Progressive Fibrosing Interstitial Lung Disease.” 2020.
[6] Bhorade, S. et al. “Risk of Lung Cancer in Chronic Fibrosing Interstitial Lung Diseases.” Thorax, 2019.
All information is for educational purposes and does not replace professional medical advice.